--- title: "China Accepts InnoCare’s Orelabrutinib Application for ITP Treatment" type: "News" locale: "en" url: "https://longbridge.com/en/news/304433408.md" description: "China has accepted InnoCare Pharma’s new drug application for orelabrutinib to treat chronic primary immune thrombocytopenia (ITP). This marks the first application of the drug in autoimmune diseases, expanding its potential use beyond hematologic malignancies." datetime: "2026-11-05T10:35:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/304433408.md) - [en](https://longbridge.com/en/news/304433408.md) - [zh-HK](https://longbridge.com/zh-HK/news/304433408.md) generator: "portal-rs" --- # China Accepts InnoCare’s Orelabrutinib Application for ITP Treatment - China accepted InnoCare Pharma’s new drug application for orelabrutinib to treat chronic primary immune thrombocytopenia. \* The acceptance marks the drug’s first application in autoimmune diseases, expanding its potential use beyond hematologic malignancies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050534PRIMZONEFULLFEED9871114) on November 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) ### Related Stocks - [09969.HK](https://longbridge.com/en/quote/09969.HK.md) - [688428.CN](https://longbridge.com/en/quote/688428.CN.md) ## Related News & Research - [2026 ASH Oral Presentation | InnoCare Announces Phase III Results of Orelabrutinib in ITP Study Meet Primary Endpoint](https://longbridge.com/en/news/304435812.md) - [InnoCare Doses First Patient in Phase I Trial of Cancer Drug ICP-B381 in China](https://longbridge.com/en/news/305175446.md) - [Hanil Feed's (KOSDAQ:005860) Conservative Accounting Might Explain Soft Earnings](https://longbridge.com/en/news/306378716.md) - [A Seattle Startup Brings Your Pet to Life on Your Phone and Laptop With the Avatar Mirroring Their Every Move in Real Time](https://longbridge.com/en/news/306379421.md) - [CEO & Chairman Of Legion Consortium Sold 32% Of Their Shares](https://longbridge.com/en/news/306378655.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**